SURVYR

ELV

Elevance Health, Inc.
$439.95
−$5.33 (1.20%)Oct 23 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-19%-6%+7%+20%+33%Oct 2025Oct 2026Apr 202652w high $450.6952w low $274.84
ELVSPY
Wall St. Highest PT $523.00 (+18.9%) Wall St. Avg PT $481.48 (+9.4%)
$277$342$408$473$539POC $391Hi $523Avg $481
Underwater Drawdown %Max DD -26.5%Current -1.2%
0.0%-26.5%
Relative Strength vs SPY+14.9% vs SPYOutperforming
+23%0%-23%
1W
+$11.69 (2.73%)
1M
+$41.39 (10.38%)
3M
+$63.91 (16.99%)
6M
+$98.08 (28.69%)
YTD
+$94.46 (27.34%)
1Y
+$100.42 (29.58%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
21 analysts · mean score 1.82
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$439.95
Average target$481.48
+$41.53 (+9.4%) upsideaverage target vs current price
CurrentAverageMedian
Low$406.00
Median$490.00
High$523.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$95.4B
P/E (last 12 months)18.7
P/E (next 12 months, estimated)14.6
52-week range$274.84 – $450.69
Revenue growth (latest quarter vs a year ago)+1.4%
Dividend yield1.56%
Analyst consensusBuy (21)
Average analyst price target$481.48 (+9%)

What they do

Elevance Health, Inc. operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products.

Healthcare · Healthcare Plans
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
59th percentile in sector
B-
12-1 return: +25.0%
Percentile within its GICS sector across the S&P 1500.
Growth
16th percentile in sector
D-
Revenue growth (YoY): +1.4%
Percentile within its GICS sector across the S&P 1500.
Value
71st percentile in sector
B
Forward E/P: 6.9% · EBITDA/EV: 9.6%
Percentile within its GICS sector across the S&P 1500.
Profitability
42nd percentile in sector
C
Profit margin: +2.5% · Return on equity: +11.1%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 162 of 499 · 12-month momentum 23.4%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

ELV earningsReported Oct 21, 2026▲ Above estimates
Results · Before the open
EPS actual$6.99
EPS estimate$4.69
Surprise+48.9%
RevenueNot in our data yet

Revenue for this quarter is not in our data yet. It arrives with the quarterly filing.

Next report
Thu Jan 28, 2027Before the open
EPS consensus$2.07
Revenue consensus–
Last 4 quarters · EPS vs estimate
Oct 21, 2026$6.99est $4.69+48.9%Above estimates
Jul 15, 2026$7.45est $6.21+20.0%Above estimates
Apr 22, 2026$12.58est $10.81+16.4%Above estimates
Jan 28, 2026$3.33est $3.09+7.7%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-26 18:02:48 ET
25-0125-0425-0725-1026-0126-0426-0726-100.0012.58
EstimateActual (beat)Actual (miss)

News & catalysts

More news
How Much Should This Move Change Your View Of Centene Stock?
Trefis · Oct 26
Elevance (ELV) Q3 2026 Earnings Call Transcript
Nasdaq · Oct 21
What Elevance Health (ELV) Said on Its Q3 Earnings Call
Nasdaq · Oct 21
What Could Stop CVS Health Stock Over The Next Six Months?
Trefis · Oct 21
Elevance Health Q3 26 Earnings Conference Call At 8:30 AM ET
Nasdaq · Oct 21
Insider trades
Kaye Mark
EVP & CFO · 2026-10-22
Sell
$122.1K
Kaye Mark
EVP & CFO · 2026-10-22
Sell
$368.9K
Kaye Mark
EVP & CFO · 2026-10-22
Sell
$71.2K
Kaye Mark
EVP & CFO · 2026-10-22
Sell
$195.3K
Kaye Mark
EVP & CFO · 2026-10-22
Sell
$212.5K
Kaye Mark
EVP & CFO · 2026-10-22
Sell
$1.0M
Kaye Mark
EVP & CFO · 2026-10-22
Sell
$757.6K
Kaye Mark
EVP & CFO · 2026-10-22
Sell
$509.5K
Kaye Mark
EVP & CFO · 2026-10-22
Sell
$105.2K
Kaye Mark
EVP & CFO · 2026-10-22
Sell
$244.8K
Kaye Mark
EVP & CFO · 2026-10-22
Sell
$724.1K
Kaye Mark
EVP & CFO · 2026-10-22
Sell
$139.7K

Stats refreshed 2026-10-26 18:02:48 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026